Fernando J. Martinez, MD, MS

The panel concludes the discussion with key takeaways on the evolving treatment landscape for COPD.

Experts on respiratory diseases discuss the role of primary care providers in the treatment of patients with COPD.

Clinical insights on the relationship between comorbidities in COPD and how multimorbidity plays a role in treatment decisions.

Focusing on evolving therapeutic paradigms for patients with COPD, experts discuss the importance of earlier diagnosis and treatment.

Experts share perspectives on the future treatment landscape for patients with COPD, highlighting the importance of precision medicine and the remaining unmet needs.

The panel discusses emerging treatment approaches in COPD and reviews the study design and topline results from the BOREAS trial investigating dupilumab.

Igor Barjaktarevic, MD, PhD, discusses the evolving treatment landscape in COPD, highlighting current treatment approaches and novel therapies on the horizon.

Experts on respiratory diseases discuss the GOLD treatment guidelines for COPD and discuss research that is informing treatment strategies.

Focusing on the role of eosinophils in diagnosing COPD, the panel discusses how often they should be tested, the cut-off value, and the natural changes of eosinophils in the disease course.

The panel discusses unmet needs in the COPD treatment landscape, highlights the shortcomings of current treatment strategies, and provides insights on diagnostic practices.

Igor Barjaktarevic, MD, PhD, provides insights on the evolving role of biomarkers in COPD, highlighting the role of eosinophils on informing treatment decisions.

1) Nicola A. Hanania, MD, MS, discusses what we have learned from asthma research on the involvement of type 2 inflammation that is applicable to COPD.

The expert panel offers insights on the concept of extending phenotypes into treatable traits in patients with COPD.

Three experts on respiratory diseases give an overview of chronic obstructive pulmonary disease (COPD) and its impact on patients and the healthcare system.

Steven D. Nathan, MD, FCCP, and Fernando J. Martinez, MD, MS, share clinical pearls and advice for the management of IPF.

Expert pulmonologists comment on emerging therapies in the pipeline for the treatment of IPF.

Fernando J. Martinez, MD, MS, and Steven D. Nathan, MD, FCCP, share their personal experiences using pirfenidone and nintedanib in clinical practice and discuss the role of managing comorbidities for the treatment of IPF.

Experts in pulmonology discuss the safety and efficacy of pirfenidone and nintedanib for the management of IPF.

Drs Fernando J. Martinez and Steven D. Nathan review the goals of therapy and the importance of non-pharmacological therapies for the management of IPF.

Steven D. Nathan, MD, FCCP, leads the discussion on the differential diagnosis of idiopathic pulmonary fibrosis (IPF).

Expert pulmonologists discuss the effect of early and late diagnosis on IPF disease management, as well as the importance of a multidisciplinary team approach to treatment.